Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

DiaMedica Therapeutics Inc (DMAC)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow DiaMedica Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.590 -0.470    -9.29%
29/07 - Closed. Currency in USD
Pre Market
4.390
-0.200
-4.357%
9:45:09 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 722,484
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 4.590 - 5.150
DiaMedica Therapeutics 4.590 -0.470 -9.29%

DiaMedica Therapeutics Inc Company Profile

 
Get an in-depth profile of DiaMedica Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

28

Equity Type

ORD

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Contact Information

Address 301 Carlson Parkway Suite 210
Minneapolis, 55305
United States
Phone 763 496 5454
Fax -

Top Executives

Name Age Since Title
Tanya N. Lewis 52 2023 Director
Vincenzo Berghella - 2024 Member of Preeclampsia Scientific Advisory Board
Dietrich John Pauls 54 2005 President, CEO & Director
James T. Parsons 60 2015 Independent Chairman
R. Michael Giuffre 69 2010 Independent Director
John Volpi - - Member of Stroke Clinical Advisory Board
Philip Bath - 2023 Member of Stroke Advisory Board
Scott Eric Kasner - - Member of Stroke Clinical Advisory Board
Charles Pauling Semba 64 2021 Independent Director
Richard Edward Kuntz 68 2023 Independent Director
Stephen Tong - 2024 Member of Preeclampsia Scientific Advisory Board
Michael D. Hill - 2024 Member of the Stroke Advisory Board
Bob Silver - 2024 Member of Preeclampsia Scientific Advisory Board
Cathy Cluver - 2024 Member of Preeclampsia Scientific Advisory Board
Daniel J. O’Connor 60 2025 Independent Director
Susan Walker - 2024 Member of Preeclampsia Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

DMAC Comments

Write your thoughts about DiaMedica Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email